ILC Therapeutics
Glasgow, United Kingdom· Est. 2016
Our platform technology allows us to engineer novel Hybrid Interferons targeted against specific diseases, each with a large unmet medical need and clear commercial market.
Private Company
Total funding raised: $3.3M
About
Our platform technology allows us to engineer novel Hybrid Interferons targeted against specific diseases, each with a large unmet medical need and clear commercial market.
RNA & Gene Therapy
Funding History
2Total raised:$3.3M
Seed$2.8MMar 15, 2021
Grant$500KSep 15, 2020